{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28","upperLimit":"61","value":"45"},{"groupId":"OG001","lowerLimit":"38","upperLimit":"95","value":"80"},{"groupId":"OG002","lowerLimit":"6","upperLimit":"84","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"OS1 is the percent probability estimate at 1 year based on the Kaplan-Meier method. OS is defined as the time from or registration to death due to any cause, or censored at date last known alive.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG000","title":"[Dose Level II] Pembrolizumab + Trebananib (Colorectal)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG001","title":"[Dose Level II] Pembrolizumab + Trebananib (Ovarian)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG002","title":"[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)"}],"paramType":"NUMBER","populationDescription":"The analysis population will include patients enrolled in the dose escalation and dose expansion portions of the trial. Per protocol, the dose escalation and dose expansion data may be combined for patients with the same cancer type who received the same treatment doses.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Survival at 1 Year (OS1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}